Lv2
200 积分 2023-12-21 加入
Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity
12天前
已完结
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
25天前
已完结
Mazdutide versus placebo in Chinese adults with type 2 diabetes
30天前
已完结
Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes
2个月前
已完结
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
3个月前
已关闭
Prediction of Local Drug Exposure of Dry Powder Inhaler CXG87 (budesonide/formoterol) Using Physiologically‐Based Pharmacokinetic Model
3个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
3个月前
已完结
A single blinded randomised trial to compare the efficacy and safety of once daily budesonide (400microg) administered by turbuhaler with beclomethasone dipropionate (400microg) given twice daily through a metered-dose inhaler in patients with mild to moderate asthma
3个月前
已关闭
Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures
4个月前
已完结
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study
4个月前
已完结
皖公网安备34019202002308
